PRNewsWire
08 Dec 2025, 22:31 UTC · 41w ago
Verdict
Headline takes no side. We score GRF +0.60 across four claims — strongly bullish.
+0.60strongly bullish
More positive than 74% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
There are currently no approved therapies for Acute on Chronic Liver Failure (ACLF), creating a significant therapeutic void.
More positive than 93% of claims this week
Genfit is leading the ACLF R&D pipeline with four distinct assets, including programs currently in Phase 2.
So whatPositioning as a leader in a high-unmet-need market with late-stage candidates is a positive catalyst for the company's valuation.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 77% of claims this week
Other notable candidates in clinical trials for ACLF include Yaqrit's YAQ005 and Grifols Therapeutics' ALBUTEINE.
More positive than 63% of claims this week
The global ACLF market is projected to grow through 2034 driven by rising prevalence of chronic liver diseases like cirrhosis and hepatitis.
More positive than 51% of claims this week
Which stocks this story touches
More positive than 74% of ticker scores this week
Mentioned as having a candidate (ALBUTEINE) in clinical trials for a growing market with significant unmet needs.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Zacks Investment Research
26m ago
−0.5%
Price flat so far
$10.15 vs $10.20 close before publication (Dec 8) · not market-adjusted
GRF chart →
